Respuesta parcial de etanercept en el tratamiento de la hidradenitis supurativa

López-Martín, C.; Goitia, Begoña Tortajada; Felipe, Vicente Faus; Sanchez, A Gomez; Soler, F. Ferrer; Siles, Margarita Garrido

doi:10.1016/j.farma.2010.10.003

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulated experience showed two cases with a favorable response and six small studies with variable results. In some studies there was a favorable response in a smaller percentage compared to other drugs, with a time of relapse after stopping therapy ranging from 2 to 8 weeks [22,23,24,25,26,27,28,29]. The only double-blind, randomized, placebo-controlled study reported by Adams et al [29] included 10 patients receiving etanercept for 12 weeks with doses of 50 mg twice a week and 10 cases receiving a placebo.…”

Section: Review and Discussionmentioning

confidence: 99%

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

et al. 2014

View full text Add to dashboard Cite

Several studies report the usefulness of different biological therapies in the management of a difficult-to-treat pathology such as hidradenitis suppurativa (HS). However, there are little data on this, which shows the great difficulty in the management of this disease. We will report herein our experience of the treatment of four complex cases of HS. We will also review previous cases published in the literature in order to further assess the results obtained with different biological drugs in terms of efficacy and safety. We conclude that, in the near future, biological therapy could become an essential tool in the management of cases of HS who have not previously responded to classical treatment.

show abstract

Section: Review and Discussionmentioning

confidence: 99%

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

et al. 2014

View full text Add to dashboard Cite

show abstract

Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review

Blok

Hattem

Jonkman

et al. 2013

British Journal of Dermatology

101

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a difficult disease to treat. Although the pathogenesis of this inflammatory skin disease is largely unknown, the important role of the immune system has been demonstrated in both experimental and clinical studies. Clinicians are therefore increasingly prescribing systemic treatments with immunosuppressive agents, but the more traditionally used systemic retinoids, especially isotretinoin, also remain relatively common therapies. In order to provide an overview of all currently available systemic immunosuppressive agents and retinoids for the treatment of HS, a systematic search was performed using the Medline and Embase databases. All published papers concerning systemic retinoids or immunosuppressive treatments for HS in adults were included. The primary endpoints were the percentages of significant responders, moderate responders and nonresponders. Other endpoints were the relapse rate and adverse events. In total 87 papers were included, comprising 518 patients with HS who were treated with systemic retinoids, biological agents or another immunosuppressive agents, including colchicine, ciclosporin, dapsone or methotrexate. The highest response rates were observed with infliximab, adalimumab and acitretin. Overall, the quality of evidence was low and differed between the agents, making direct comparisons difficult. However, based on the amount of evidence, infliximab and adalimumab were the most effective agents. Acitretin was also effective in HS, although the quality of the evidence was low. The therapeutic effect of isotretinoin is questionable. Randomized controlled trials are needed to confirm the effectiveness of acitretin, and to identify the most effective immunosuppressive agents in HS.

show abstract

Biologics for Hidradenitis Suppurativa: An Update

et al. 2018

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatosis characterized by an occurrence of nodules, abscesses, sinus tracks and scarring. Its pathogenesis is multifactorial and still not fully understood, therefore, current systemic therapies still remain a serious challenge. Increased levels of several proinflammatory cytokines have been reported in patients suffering from HS, therefore biologics appear as a new approach to therapy for this condition. Adalimumab is the only one internationally registered agent and should be considered first after the conventional therapies appear insufficient. The efficacy and safety profile of some preparations, like infliximab and etanercept was confirmed so far in randomized trials, but there are some new biologics which are still being evaluated and require more rigorous examination.

show abstract

Respuesta parcial de etanercept en el tratamiento de la hidradenitis supurativa

Cited by 3 publications

References 9 publications

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

Management of Hidradenitis Suppurativa with Biological Therapy: Report of Four Cases and Review of the Literature

Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review

Biologics for Hidradenitis Suppurativa: An Update

Contact Info

Product

Resources

About